Corcept Therapeutics (CORT) Amortization of Deferred Charges (2012 - 2021)
Corcept Therapeutics (CORT) posted Amortization of Deferred Charges of $193000.0 for Q4 2025, up 2.66% sequentially from $188000.0 in Q3 2025, and up 7.82% YoY from $179000.0 in Q4 2024.
Powered by 
Analysis
Corcept Therapeutics (CORT) Amortization of Deferred Charges (2012 - 2021) Analysis & Trends
Corcept Therapeutics has reported Amortization of Deferred Charges for 11 years, with the latest figure at $193000.0 in Q4 2025.
- Quarterly Amortization of Deferred Charges rose 7.82% year-over-year to $193000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $741000.0 (up 36.97% YoY) and the FY2025 annual result came in at $741000.0, up 36.97% from the prior year.
- Amortization of Deferred Charges grew to $193000.0 in Q4 2025 per CORT's latest filing, from $188000.0 in the prior quarter.
- Over five years, Amortization of Deferred Charges peaked at $637000.0 in Q2 2023 and troughed at $57000.0 in Q3 2023.
- A 5-year average of $339200.0 and a median of $341000.0 in 2021 frame the typical range for Amortization of Deferred Charges.
- The sharpest annual moves came in 2023 and 2024: Amortization of Deferred Charges plunged 89.77% in 2023, then surged 217.54% in 2024.
- Over 5 years, Amortization of Deferred Charges stood at $508000.0 in 2021, then climbed by 11.02% to $564000.0 in 2022, then slumped by 89.72% to $58000.0 in 2023, then soared by 208.62% to $179000.0 in 2024, then grew by 7.82% to $193000.0 in 2025.
- According to Business Quant data, Amortization of Deferred Charges over the past three periods registered $193000.0, $188000.0, and $183000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Corcept Therapeutics | 11.76 Bn | 11.46 Bn | 252.09 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2021 | 508,000.00 |
| Sep 30, 2021 | 502,000.00 |
| Jun 30, 2021 | 496,000.00 |
| Mar 31, 2021 | 489,000.00 |
| Dec 31, 2020 | 484,000.00 |
| Sep 30, 2020 | 479,000.00 |
| Jun 30, 2020 | 385,000.00 |
| Mar 31, 2020 | 364,000.00 |
| Dec 31, 2019 | 332,000.00 |
| Sep 30, 2019 | 364,000.00 |
| Jun 30, 2019 | 359,000.00 |
| Mar 31, 2019 | 413,000.00 |
| Sep 30, 2017 | 3,000.00 |
| Jun 30, 2017 | 6,000.00 |
| Mar 31, 2017 | 5,000.00 |
| Dec 31, 2016 | 5,000.00 |
| Sep 30, 2016 | 5,000.00 |
| Jun 30, 2016 | 6,000.00 |
| Mar 31, 2016 | 5,000.00 |
| Dec 31, 2015 | 2,000.00 |